Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.75 |
| ▸ | CCR9 | P51686 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.57 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13576482 | 0.94 | SLC10A6 (0.87) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL28006 | 0.93 | LMNA (0.86) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL27979 | 0.89 | LMNA (0.83) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL27758 | 0.88 | LMNA (0.78) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL13576522 | 0.88 | SLC10A6 (1.00) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL5125081 | 0.87 | KCNA5 (0.65) | SLC10A6LMNAHTTKCNA5KMT2A | |
| SCHEMBL13137558 | 0.87 | LMNA (0.80) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL28518 | 0.87 | LMNA (0.80) | SLC10A6LMNAHTTCCR9MAPT | |
| SCHEMBL12242366 | 0.87 | LMNA (0.80) | LMNAHTTCCR9MAPTTP53 | |
| SCHEMBL5125608 | 0.87 | LMNA (0.63) | SLC10A6LMNAHTTCCR9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095015-B1 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-6809089-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6548547-B1 | Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1B2 | SLC10A6 3299/4885LMNA 811/4885HTT 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.